Patents by Inventor David Horne

David Horne has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • RIBONUCLEOTIDE REDUCTASE INHIBITORS AND METHODS OF USE
    Publication number: 20180155303
    Abstract: Provided herein are novel compounds that inhibit ribonucleotide reductase (RR) by binding to RRM2 and interfering with the activity of the RRM1/RRM2 holoenzyme, as well as methods of synthesizing these novel compounds. The compounds may be used to inhibit RR activity and to treat various conditions associated with RRM2 expression, such as for example certain cancer types, mitochondrial diseases, or degenerative diseases.
    Type: Application
    Filed: October 4, 2017
    Publication date: June 7, 2018
    Inventors: David Horne, Christopher Lincoln
  • ETP DERIVATIVES
    Publication number: 20180155367
    Abstract: Provided herein, inter alia, is the synthesis of ETP derivatives. The uses of the ETP derivatives described herein include treatment of cancer.
    Type: Application
    Filed: October 27, 2017
    Publication date: June 7, 2018
    Inventors: Larry Eugene Overman, Marcus Baumann, Sangkil Nam, David Horne, Richard Jove, Jun Xie, Claudia Kowolik
  • DNA2 INHIBITORS FOR CANCER TREATMENT
    Publication number: 20180134664
    Abstract: Disclosed herein, inter alia, are compositions and methods for inhibiting DNA2.
    Type: Application
    Filed: January 9, 2018
    Publication date: May 17, 2018
    Inventors: Binghui Shen, Judith Campbell, Li Zheng, Hongzhi Li, David Horne, Jun Xie, Kenneth Karanja
  • DNA2 inhibitors for cancer treatment
    Patent number: 9932310
    Abstract: Disclosed herein, inter alia, are compositions and methods for inhibiting DNA2.
    Type: Grant
    Filed: February 8, 2017
    Date of Patent: April 3, 2018
    Assignees: City of Hope, California Institute of Technology
    Inventors: Binghui Shen, Judith Campbell, Li Zheng, Hongzhi Li, David Horne, Jun Xie, Kenneth Karanja
  • MECHANICALLY INTERLOCKING COMPLEXES
    Publication number: 20180086826
    Abstract: Provided herein are functionalized monoclonal antibodies (mAbs) including antibody fragments, including those where a Fab-binding molecule (Fab binding moiety) linked to a steric hindering molecule (steric hindering chemical moiety) is mechanically interlocked (e.g., through noncovalent conjugation) with the antibody or antibody fragment. Also provided are compositions that form highly stable and versatile drug delivery and diagnostic compositions.
    Type: Application
    Filed: March 30, 2016
    Publication date: March 29, 2018
    Inventors: John Williams, Krzysztof p. Bzymek, David Horne, Jun Xie
  • ETP derivatives
    Patent number: 9856273
    Abstract: Provided herein, inter alia, is the synthesis of ETP derivatives. The uses of the ETP derivatives described herein include treatment of cancer.
    Type: Grant
    Filed: August 19, 2016
    Date of Patent: January 2, 2018
    Assignees: CITY OF HOPE, THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Larry Eugene Overman, Marcus Baumann, Sangkil Nam, David Horne, Richard Jove, Jun Xie, Claudia Kowolik
  • Isatin derivatives, pharmaceutical compositions thereof, and methods of use thereof
    Patent number: 9828342
    Abstract: One aspect of the invention relates to novel isatin derivative compounds and the pharmaceutical composition thereof. Another aspect of the invention relates to methods of using the isatin derivative compounds disclosed herein and the pharmaceutical compositions thereof. In certain embodiments, the method is used to treat a cancer or a tumor in a subject including, without limitation, prostate cancer, melanoma, pancreatic cancer, ovarian cancer, and lymphoma. In certain embodiment, the method is used to treat a condition in a subject that can be regulated by the activation of one or more proteins such as EGFR, Erk1/2, Her2/Neu, Jak2, Src, Stat3, Akt, Cyclin B1, and Cdc25C. In certain embodiment, the method is used to treat a condition in a subject that can be regulated by the disruption of microtubule formations.
    Type: Grant
    Filed: February 25, 2013
    Date of Patent: November 28, 2017
    Assignees: CITY OF HOPE, THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: David A. Horne, Richard Jove, Christopher Lincoln, Sangkil Nam, Larry Overman, Jun Xie
  • Compound for treating cancer and diabetes
    Patent number: 9808434
    Abstract: One aspect of the disclosure relates to the use of derivatives of dichlorophenyl urea for treating cancers.
    Type: Grant
    Filed: June 4, 2016
    Date of Patent: November 7, 2017
    Assignee: CITY OF HOPE
    Inventors: Samuel Rahbar, James L. Figarola, Christopher Lincoln, David Horne, Rachael Mooney, Monika Polewski, George Somlo, Lixin Yang, Sanjay Awasthi, Sharad Singhal, Jyotasana Singhal
  • Ribonucleotide reductase inhibitors and methods of use
    Patent number: 9796692
    Abstract: Provided herein are novel compounds that inhibit ribonucleotide reductase (RR) by binding to RRM2 and interfering with the activity of the RRM1/RRM2 holoenzyme, as well as methods of synthesizing these novel compounds. The compounds may be used to inhibit RR activity and to treat various conditions associated with RRM2 expression, such as for example certain cancer types, mitochondrial diseases, or degenerative diseases.
    Type: Grant
    Filed: January 27, 2017
    Date of Patent: October 24, 2017
    Assignee: CITY OF HOPE
    Inventors: David Horne, Christopher Lincoln
  • DNA2 INHIBITORS FOR CANCER TREATMENT
    Publication number: 20170226063
    Abstract: Disclosed herein, inter alia, are compositions and methods for inhibiting DNA2.
    Type: Application
    Filed: February 8, 2017
    Publication date: August 10, 2017
    Inventors: Binghui Shen, Judith Campbell, Li Zheng, Hongzhi Li, David Horne, Jun Xie, Kenneth Karanja
  • Meditopes and meditope-binding antibodies and uses thereof
    Patent number: 9669108
    Abstract: Antibodies and meditopes that bind to the antibodies are provided, as well as complexes, compositions and combinations containing the meditopes and antibodies, and methods of producing, using, testing, and screening the same, including therapeutic and diagnostic methods and uses.
    Type: Grant
    Filed: August 6, 2014
    Date of Patent: June 6, 2017
    Assignee: City of Hope
    Inventors: John C. Williams, David A. Horne, Yuelong Ma, Heng Wei Chang, Joshua M. Donaldson, Cindy Zer, Krzysztof Bzymek, Kendra N. Avery, Jun Xie
  • RIBONUCLEOTIDE REDUCTASE INHIBITORS AND METHODS OF USE
    Publication number: 20170137392
    Abstract: Provided herein are novel compounds that inhibit ribonucleotide reductase (RR) by binding to RRM2 and interfering with the activity of the RRM1/RRM2 holoenzyme, as well as methods of synthesizing these novel compounds. The compounds may be used to inhibit RR activity and to treat various conditions associated with RRM2 expression, such as for example certain cancer types, mitochondrial diseases, or degenerative diseases.
    Type: Application
    Filed: January 27, 2017
    Publication date: May 18, 2017
    Inventors: David Horne, Christopher Lincoln
  • Multiple radio devices for implementing dynamic band access background
    Patent number: 9648589
    Abstract: A system and method are provided to implement dynamic spectrum access with individual multi-mode devices that incorporate multiple radios in a single device. A multi-mode device is configured to make use of the incremental spectrum by maintaining a data communication link via a base station that is operated by a primary operator to support communications in the primary operator's exclusively-licensed spectrum. This data communication link is maintained by a first radio, the data communication link being used to support a first level of data communication as well as to signal an availability of additional spectrum to the multi-mode device. The multi-mode device may request access to additional spectrum. A second radio may facilitate access to received additional spectrum with the multi-radio multi-mode device.
    Type: Grant
    Filed: June 6, 2012
    Date of Patent: May 9, 2017
    Assignee: Intel Corporation
    Inventors: Geoff Weaver, Carlos Cordeiro, Srikathyayani Srikanteswara, Bahareh Sadeghi, Reza Arefi, David Horne, Takashi Shono
  • Ribonucleotide reductase inhibitors and methods of use
    Patent number: 9598385
    Abstract: Provided herein are novel compounds that inhibit ribonucleotide reductase (RR) by binding to RRM2 and interfering with the activity of the RRM1/RRM2 holoenzyme, as well as methods of synthesizing these novel compounds. The compounds may be used to inhibit RR activity and to treat various conditions associated with RRM2 expression, such as for example certain cancer types, mitochondrial diseases, or degenerative diseases.
    Type: Grant
    Filed: June 29, 2015
    Date of Patent: March 21, 2017
    Assignee: CITY OF HOPE
    Inventors: David Horne, Christopher Lincoln
  • Electrorecovery of metals
    Patent number: 9580772
    Abstract: A method and ionic liquid for the electrorecovery of metal from a metal salt including at least one metal ion. The method includes the steps of dissolving the metal salt in an ionic liquid, the ionic liquid including an ionic liquid cation and an ionic liquid anion; whereby the metal ion of the metal salt forms a metal complex in solution with at least the ionic liquid cation; and subjecting the metal complex to an electrical potential between a cathode and anode to recover metal at the cathode. The ionic liquid includes an ionic liquid cation and an ionic liquid anion, wherein the ionic liquid cation has an affinity for the metal ion which is at least about equal to that of the ionic liquid anion for the metal ion.
    Type: Grant
    Filed: March 17, 2010
    Date of Patent: February 28, 2017
    Assignee: Commonwealth Scientific and Industrial Research Organisation
    Inventors: Theo Rodopoulos, Michael David Horne, Thomas Ruether
  • ETP derivatives
    Patent number: 9527868
    Abstract: Provided herein, inter alia, is the synthesis of ETP derivatives. The uses of the ETP derivatives described herein include treatment of cancer.
    Type: Grant
    Filed: April 17, 2015
    Date of Patent: December 27, 2016
    Assignees: CITY OF HOPE, THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Larry Eugene Overman, Marcus Baumann, Sangkil Nam, David Horne, Richard Jove, Jun Xie, Claudia Kowolik
  • COMPOUND FOR TREATING CANCER AND DIABETES
    Publication number: 20160354327
    Abstract: One aspect of the disclosure relates to the use of derivatives of dichlorophenyl urea for treating cancers.
    Type: Application
    Filed: June 4, 2016
    Publication date: December 8, 2016
    Inventors: Samuel RAHBAR, James L. Figarola, Christopher Lincoln, David Horne, Rachael Mooney, Monika Polewski, George Somlo, Lixin Yang
  • RIBONUCLEOTIDE REDUCTASE INHIBITORS AND METHODS OF USE
    Publication number: 20160122308
    Abstract: Provided herein are novel compounds that inhibit ribonucleotide reductase (RR) by binding to RRM2 and interfering with the activity of the RRM1/RRM2 holoenzyme, as well as methods of synthesizing these novel compounds. The compounds may be used to inhibit RR activity and to treat various conditions associated with RRM2 expression, such as for example certain cancer types, mitochondrial diseases, or degenerative diseases.
    Type: Application
    Filed: June 29, 2015
    Publication date: May 5, 2016
    Inventors: David Horne, Christopher Lincoln
  • 5-BROMO-INDIRUBINS
    Publication number: 20160068517
    Abstract: Disclosed herein inter alia are compositions and methods for treating cancer using 5-Br-indirubin derivatives.
    Type: Application
    Filed: September 10, 2015
    Publication date: March 10, 2016
    Inventors: Richard Jove, Sangkil Nam, David Horne, Jun Xie, Alexios Leandros Skaltsounis, Marina Kritsanida, Nicolas Gaboriaud-Kolar
  • Photocleavable linker
    Patent number: 9260710
    Abstract: There are provided, inter alia, photolabile compounds and methods useful for the formation of dimers of biological molecules and subsequent dissociation of the dimers.
    Type: Grant
    Filed: June 29, 2015
    Date of Patent: February 16, 2016
    Assignee: City of Hope
    Inventors: John C. Williams, David Horne, Jun Xie, Shubbir Ahmed